Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Gedunin is a naturally occurring pentacyclic triterpenoid and limonoid, mainly isolated from the neem tree (*Azadirachta indica*) and other plant species[2][8]. It has demonstrated **anticancer**, **antimalarial**, **antifungal**, and **antineoplastic** properties[2][3][8]. Gedunin acts as a **heat shock protein 90 (Hsp90) inhibitor**, inducing degradation of Hsp90-dependent client proteins, and inhibits cancer cell proliferation and metastasis[1][3][7]. It does not competitively bind ATP at the Hsp90 binding site, and its α,β-unsaturated ketone moiety is required for antiproliferative activity but does not appear to act as a Michael acceptor[1]. Studies have shown anticancer efficacy in pancreatic cancer, where gedunin blocks the **sonic hedgehog (Shh)/Gli1 signaling pathway**, epithelial-mesenchymal transition (EMT), migration, invasion, and colony formation, resulting in reduced metastasis and tumor growth in xenograft models[3]. Gedunin is under investigation for its potential as a chemotherapeutic and antimalarial agent[2][7][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on gedunin.